Melissa Epperly - Feb 10, 2022 Form 4 Insider Report for Zentalis Pharmaceuticals, Inc. (ZNTL)

Role
Chief Financial Officer
Signature
By: /s/ Melissa B. Epperly
Stock symbol
ZNTL
Transactions as of
Feb 10, 2022
Transactions value $
$0
Form type
4
Date filed
2/14/2022, 08:09 PM
Previous filing
Oct 4, 2021
Next filing
Feb 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZNTL Common Stock Award $0 +16.4K +6.56% $0.00 266K Feb 10, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZNTL Stock Option (Right to Buy) Award $0 +38.5K $0.00 38.5K Feb 10, 2022 Common Stock 38.5K $52.61 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date.
F2 The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date.